LSL Pharma Group

LSL Pharma Group EBITDA per Employee

EBITDA per Employee of LSL Pharma Group (LSL.V) as of Nov 1, 2026.

EBITDA per Employee

-CAD

Last updated:

EBITDA per Employee of LSL Pharma Group is 2026 - CAD. EBITDA per Employee of LSL Pharma Group was 2025 - CAD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LSL Pharma Group Stock analysis

What does LSL Pharma Group do? LSL Pharma Group, Inc. generates revenue through the development, manufacturing, and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The company operates as a pharmaceutical entity specializing in these specific therapeutic and wellness categories to meet market demand. The firm utilizes its subsidiaries, including Steri-Med Pharma Inc., LSL Laboratory Inc., and Groupe Immobilier LSL inc., to support its core operations. These entities facilitate the company's ability to produce and distribute its specialized pharmaceutical and supplement offerings effectively within its operational framework. LSL Pharma Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about LSL Pharma Group stock

On Eulerpool you can find the complete historical development of EBITDA per Employee LSL Pharma Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's LSL Pharma Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — LSL Pharma Group

All Key Metrics — LSL Pharma Group